PegBio Co

PegBio Co Debt / Assets

The Debt-to-Assets Ratio of PegBio Co (2565.HK) as of Nov 18, 2026 is 0.46. In the previous year, Debt-to-Assets Ratio was 0.18 — a change of 150.32% (higher).

Debt / Assets

0.46

YoY

150.32%

Last updated:

Debt-to-Assets Ratio of PegBio Co is 2024 0.46 . Debt-to-Assets Ratio of PegBio Co was 2023 0.18 . It decreases by 150.32% higher compared to the previous year.

The PegBio Co Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2023
0.18 CNY
Jan 1, 2024
0.46 CNY
The PegBio Co Debt / Assets history
YEARDebt / AssetsYoY
0.46+150.32%
0.18—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PegBio Co Stock analysis

What does PegBio Co do? PegBio Co., Ltd. generates revenue primarily through the development and commercialization of innovative drugs targeting chronic and metabolic diseases. The company's flagship product, PB-119, is a near-commercialized long-acting GLP-1 receptor agonist designed for treating type 2 diabetes and obesity. Product candidates such as PB-718, PB-1902, PB-722, PB-2301, and PB-2309 are in development for indications including non-alcoholic steatohepatitis, opioid-induced constipation, and congenital hyperinsulinemia. The company focuses on pharmaceutical markets for chronic disease treatment, targeting patients and healthcare providers seeking advanced therapeutic solutions. PegBio's revenue streams are derived from the sale of PB-119 once it reaches commercialization, alongside potential future sales of its pipeline products. The firm targets healthcare systems and medical professionals in China, where it is headquartered, to address high-prevalence conditions like type 2 diabetes and obesity. Its product portfolio addresses unmet medical needs in metabolic disorders, positioning PegBio to capture market share in the growing biotechnology sector. The company's business model centers on developing proprietary drug candidates with strong clinical potential. PB-119, as a near-commercialized asset, is expected to drive initial revenue, while the broader pipeline of products like PB-718 and PB-2301 targets expanding therapeutic areas. PegBio aims to establish itself as a leader in chronic disease therapeutics through a focused approach on metabolic and endocrine conditions. PegBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PegBio Co stock

Debt-to-Assets Ratio of PegBio Co is 0.46 in 2024.

Debt-to-Assets Ratio of PegBio Co changed from 0.18 to 0.46, representing a 150.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio PegBio Co since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's PegBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — PegBio Co

All Key Metrics — PegBio Co